Rgenix Announces $33 Million Series B Financing to Develop First-in-Class Cancer Therapeutics
Novo A/S and Sofinnova Partners are leading this latest financing round NEW YORK, New York ― June 15, 2016 ― Rgenix, a cancer therapeutics company developing first-in-class drugs targeting novel cancer pathways, announced a $33 million Series B financing led by